AUM $5.7MER 0.59%NAV $24.69Holdings 20Inception May 2024
Price Chart
Key Statistics
Previous Close
$24.49Day Range
$24.50$24.50
52-Week Range
$22.94$27.91
Avg Volume
697Dividend Yield
1.67%Expense Ratio
0.59%AUM
$5.7MShares Outstanding
200.0KETF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 99.67% |
| Financial Services | 0.24% |
| Cash & Others | 0.09% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 55.61% |
| China | 12.67% |
| Denmark | 12.34% |
| Switzerland | 5.26% |
| United Kingdom | 5.26% |
| Japan | 4.96% |
| South Korea | 3.56% |
| Other | 0.33% |
Fund Information
- Issuer
- Amplify
- Category
- Healthcare
- Types
- Healthcare
- Inception Date
- May 20, 2024
- Exchange
- NYSE_ARCA
- Description
- THNR provides access to global companies expected to economically benefit from weight loss drug development. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.
Similar ETFs
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund issued by Amplify that launched on May 20, 2024. It currently manages $5.7M in assets under management. The fund charges an expense ratio of 0.59%. The fund holds 20 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 62.0% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | 10.19% | 503 | $578K |
| 2 | NVO | Novo Nordisk A/S | 8.46% | 12,835 | $480K |
| 3 | 1093.HK | CSPC Pharmaceutical Group Ltd | 5.92% | 262,000 | $336K |
| 4 | AMGN | Amgen Inc | 5.65% | 788 | $321K |
| 5 | PFE | Pfizer Inc | 5.40% | 10,896 | $306K |
| 6 | 1801.HK | Innovent Biologics Inc | 5.39% | 24,500 | $306K |
| 7 | ABBV | AbbVie Inc | 5.26% | 1,149 | $299K |
| 8 | GILD | Gilead Sciences Inc | 5.26% | 2,024 | $299K |
| 9 | AZN | AstraZeneca PLC | 5.25% | 1,888 | $298K |
| 10 | ROP.SW | Roche Holding AG | 5.24% | 708 | $297K |
| 11 | MRK | Merck & Co Inc | 5.13% | 2,025 | $291K |
| 12 | REGN | Regeneron Pharmaceuticals Inc | 4.92% | 380 | $279K |
| 13 | VKTX | Viking Therapeutics Inc | 4.90% | 9,118 | $278K |
| 14 | 4519.T | Chugai Pharmaceutical Co Ltd | 4.83% | 7,000 | $274K |
| 15 | ARWR | Arrowhead Pharmaceuticals Inc | 4.04% | 3,541 | $229K |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +0.03% | |
| 1W | -2.49% | |
| 1M | -7.06% | |
| 3M | -6.65% | |
| 6M | -1.23% | |
| YTD | -3.62% | |
| 1Y | -0.47% | |
| 3Y | -3.54% | |
| 5Y | -3.54% |
Moving Averages
20-Day MA
$25.37
Below 20-Day MA50-Day MA
$26.11
Below 50-Day MA200-Day MA
$25.42
Below 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$27.91
Current Price
$24.50
52-Week Low
$22.94
$22.94$27.91
Current Yield
1.67%
Annual Dividend
$1.2661
Frequency
1x/year
Last Ex-Date
Dec 30, 2025
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.4132 | Dec 31, 2025 |
| Dec 30, 2025 | $0.4132 | Dec 31, 2025 |
| Dec 30, 2024 | $0.2199 | Dec 31, 2024 |
| Dec 30, 2024 | $0.2199 | Dec 31, 2024 |
Dividend Payments Over Time
Category Comparison
| Metric | THNR | Healthcare(231 ETFs) | Healthcare(24 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.59% | 0.62% | 0.47% |
| AUM | $5.7M | $1.98B | $799.8M |
| Dividend Yield | 1.67% | 4.11% | 1.61% |
| Avg Volume | 697 | 491.6K | 95.8K |
| Holdings | 20 | 178 | 172 |
| Performance | |||
| 1-Month Return | -9.30% | -4.15% | -5.35% |
| 6-Month Return | -0.61% | +5.09% | +4.99% |
| YTD Return | -2.88% | +9.06% | +5.30% |
| 1-Year Return | -3.65% | +8.39% | +5.56% |
Compare with Another ETF
Search for an ETF to compare with THNR:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.